Negozia Edwards Lifesciences - EW CFD
Aggiungi a Preferiti- Riepilogo
- Dati Storici
- Eventi
- Conto Economico
- Stato Patrimoniale
- Cash Flow
- Titolarità
Spread | 0.23 | ||||||||
Commissione overnight su posizione lunga
Long position overnight fee
Vai alla piattaforma | -0.024068% | ||||||||
Commissione overnight su posizione corta
Short position overnight fee
Vai alla piattaforma | 0.001846% | ||||||||
Ora commissione overnight | 21:00 (UTC) | ||||||||
Quantità negoziata min | 1 | ||||||||
Valuta | USD | ||||||||
Margine | 20% | ||||||||
Borsa | United States of America | ||||||||
Commissioni per il trading | 0% |
*Information provided by Capital.com
Edwards Lifesciences Corp ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Chiusura Preced.* | 81.59 |
Apertura* | 81.53 |
Variazione a 1 Anno* | -26.78% |
Range Giornaliero* | 79.31 - 81.63 |
Range a 52 sett. | 67.13-131.10 |
Volume Medio (10 giorni) | 4.54M |
Volume Medio (3 mesi) | 73.06M |
Capitalizzazione di Mercato | 49.72B |
Rapporto P/E | 33.51 |
Azioni Circolanti | 608.31M |
Ricavi | 5.38B |
EPS | 2.44 |
Dividendi (Rendimento %) | N/A |
Beta | 1.02 |
Prossima Data per Utili | Apr 24, 2023 |
Tutti i dati sono forniti da Refinitiv, ad eccezione dei dati contrassegnati da un asterisco, che sono *dati forniti da Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Chiusura | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 22, 2023 | 79.32 | -1.84 | -2.27% | 81.16 | 81.73 | 79.27 |
Mar 21, 2023 | 81.59 | 0.59 | 0.73% | 81.00 | 82.33 | 80.63 |
Mar 20, 2023 | 80.93 | 0.79 | 0.99% | 80.14 | 81.60 | 79.74 |
Mar 17, 2023 | 80.60 | -0.59 | -0.73% | 81.19 | 82.47 | 80.07 |
Mar 16, 2023 | 81.75 | 3.75 | 4.81% | 78.00 | 82.14 | 77.86 |
Mar 15, 2023 | 79.38 | 2.90 | 3.79% | 76.48 | 79.40 | 76.42 |
Mar 14, 2023 | 78.02 | 0.90 | 1.17% | 77.12 | 78.15 | 76.27 |
Mar 13, 2023 | 76.49 | 3.17 | 4.32% | 73.32 | 76.92 | 73.00 |
Mar 10, 2023 | 74.24 | -1.46 | -1.93% | 75.70 | 75.78 | 73.78 |
Mar 9, 2023 | 75.94 | -1.12 | -1.45% | 77.06 | 78.03 | 75.78 |
Mar 8, 2023 | 77.13 | 0.21 | 0.27% | 76.92 | 77.33 | 75.83 |
Mar 7, 2023 | 78.81 | 0.39 | 0.50% | 78.42 | 79.91 | 78.32 |
Mar 6, 2023 | 78.68 | -1.99 | -2.47% | 80.67 | 81.19 | 78.41 |
Mar 3, 2023 | 81.76 | 0.83 | 1.03% | 80.93 | 82.05 | 80.47 |
Mar 2, 2023 | 80.12 | 1.19 | 1.51% | 78.93 | 80.72 | 78.83 |
Mar 1, 2023 | 79.77 | 0.08 | 0.10% | 79.69 | 79.96 | 78.57 |
Feb 28, 2023 | 80.37 | 3.57 | 4.65% | 76.80 | 80.88 | 76.80 |
Feb 27, 2023 | 77.21 | 0.80 | 1.05% | 76.41 | 78.27 | 76.41 |
Feb 24, 2023 | 76.11 | 0.00 | 0.00% | 76.11 | 77.08 | 75.74 |
Feb 23, 2023 | 77.46 | 2.13 | 2.83% | 75.33 | 77.57 | 75.33 |
Edwards Lifesciences Events
Ora (UTC) (UTC) | Paese | Evento |
---|---|---|
No events scheduled |
- Annuale
- Trimestrale
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Ricavi totali | 5232.5 | 4386.3 | 4348 | 3722.8 | 3435.3 |
Ricavi | 5232.5 | 4386.3 | 4348 | 3722.8 | 3435.3 |
Costo dei Ricavi, Totale | 1248.9 | 1080.6 | 1114.4 | 939.4 | 875.3 |
Profitto Lordo | 3983.6 | 3305.7 | 3233.6 | 2783.4 | 2560 |
Totale Costi Operativi | 3542.2 | 3488.7 | 3201.2 | 2967.5 | 2400.4 |
Costi Commerciali/Generali/Amministr., Totale | 1493.7 | 1228.4 | 1240.2 | 1088.5 | 985.8 |
Ricerca e Sviluppo | 903.1 | 760.7 | 752.7 | 622.2 | 552.6 |
Interessi Passivi (Utile) - Netto Operativo | -1.6 | ||||
Spese Straordinarie (Utile) | 20.6 | 405.4 | 100 | 323.1 | -13.4 |
Other Operating Expenses, Total | -124.1 | 13.6 | -6.1 | -5.7 | 1.7 |
Risultato d’Esercizio | 1690.3 | 897.6 | 1146.8 | 755.3 | 1034.9 |
Utile Netto al Lordo delle Imposte | 1702 | 916.7 | 1166.5 | 761.4 | 1034.9 |
Utile Netto al Netto delle Imposte | 1503.1 | 823.4 | 1049.7 | 738 | 877.7 |
Utile Netto al Lordo di Extra Elementi | 1503.1 | 823.4 | 1049.7 | 738 | 877.7 |
Utile Netto | 1503.1 | 823.4 | 1046.9 | 722.2 | 583.6 |
Reddito a Disposizione di Azionisti Ordinari Esclusi Extra. Elementi | 1503.1 | 823.4 | 1049.7 | 738 | 877.7 |
Reddito a Disposizione di Azionisti Ordinari Inclusi Extra. Elementi | 1503.1 | 823.4 | 1046.9 | 722.2 | 583.6 |
Utile Netto Diluito | 1503.1 | 823.4 | 1046.9 | 722.2 | 583.6 |
Azioni Medie Ponderate Diluite | 631.2 | 631.9 | 636.606 | 640.806 | 647.706 |
EPS Diluito Esclusi Elementi Straordinari | 2.38134 | 1.30305 | 1.6489 | 1.15167 | 1.35509 |
EPS Diluito Normalizzato | 2.41016 | 1.87932 | 1.79025 | 1.64039 | 1.33754 |
Totale Elementi Straordinari | -2.8 | -15.8 | -294.1 | ||
Interessi Attivi (Oneri), Netti Non Operativi | 9.8 | 20.5 | 21.3 | 17.3 | |
Altro, Netto | 1.9 | -1.4 | -1.6 | -11.2 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Ricavi totali | 1341.2 | 1329.7 | 1310.2 | 1376 | 1216.6 |
Ricavi | 1341.2 | 1329.7 | 1310.2 | 1376 | 1216.6 |
Costo dei Ricavi, Totale | 299.3 | 309.5 | 311.7 | 334.3 | 293.4 |
Profitto Lordo | 1041.9 | 1020.2 | 998.5 | 1041.7 | 923.2 |
Totale Costi Operativi | 902.4 | 955.3 | 919.9 | 833.9 | 833.1 |
Costi Commerciali/Generali/Amministr., Totale | 370.3 | 424 | 364.4 | 374.5 | 330.8 |
Ricerca e Sviluppo | 228.6 | 232.8 | 238 | 225.3 | 207 |
Spese Straordinarie (Utile) | 7.1 | 7.1 | 4.7 | 2.4 | 6.4 |
Other Operating Expenses, Total | -2.9 | -18.1 | 1.1 | -102.6 | -4.5 |
Risultato d’Esercizio | 438.8 | 374.4 | 390.3 | 542.1 | 383.5 |
Interessi Attivi (Oneri), Netti Non Operativi | -4 | 1.6 | 0.4 | 3.1 | 4.7 |
Altro, Netto | 1.3 | 0.3 | 0.2 | 0.3 | 1.1 |
Utile Netto al Lordo delle Imposte | 436.1 | 376.3 | 390.9 | 545.5 | 389.3 |
Utile Netto al Netto delle Imposte | 373.6 | 335.3 | 340.1 | 489.5 | 338.2 |
Utile Netto al Lordo di Extra Elementi | 373.6 | 335.3 | 340.1 | 489.5 | 338.2 |
Utile Netto | 373.6 | 335.3 | 340.1 | 489.5 | 338.2 |
Reddito a Disposizione di Azionisti Ordinari Esclusi Extra. Elementi | 373.6 | 335.3 | 340.1 | 489.5 | 338.2 |
Reddito a Disposizione di Azionisti Ordinari Inclusi Extra. Elementi | 373.6 | 335.3 | 340.1 | 489.5 | 338.2 |
Utile Netto Diluito | 373.6 | 335.3 | 340.1 | 489.5 | 338.2 |
Azioni Medie Ponderate Diluite | 629.4 | 631.8 | 631.7 | 629.9 | 631.3 |
EPS Diluito Esclusi Elementi Straordinari | 0.59358 | 0.53071 | 0.53839 | 0.77711 | 0.53572 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
EPS Diluito Normalizzato | 0.60325 | 0.54072 | 0.54486 | 0.78053 | 0.54453 |
- Annuale
- Trimestrale
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale Attivo Corrente | 3180.7 | 3091 | 2984 | 2286.9 | 2549.2 |
Disponibilità Liquide e Investimenti a Breve Termine | 1466.8 | 1402.6 | 1516.9 | 956.5 | 1337.5 |
Disponibilità Liquide e Mezzi Equivalenti | 862.8 | 1183.2 | 1179.1 | 714.1 | 818.3 |
Investimenti a Breve Termine | 604 | 219.4 | 337.8 | 242.4 | 519.2 |
Totale Crediti, Netto | 664.9 | 602.8 | 599.1 | 537.3 | 479.3 |
Accounts Receivable - Trade, Net | 582.2 | 514.6 | 543.6 | 456.9 | 438.7 |
Total Inventory | 726.7 | 802.3 | 640.9 | 607 | 554.9 |
Prepaid Expenses | 85.2 | 75.1 | 59.1 | 54.3 | 60.6 |
Other Current Assets, Total | 237.1 | 208.2 | 168 | 131.8 | 116.9 |
Total Assets | 8502.6 | 7237.1 | 6488.1 | 5323.7 | 5666.4 |
Property/Plant/Equipment, Total - Net | 1638.7 | 1489.4 | 1140.4 | 867.5 | 679.7 |
Goodwill, Net | 1167.9 | 1173.2 | 1167.7 | 1112.2 | 1126.5 |
Intangibles, Net | 323.6 | 331.4 | 336.5 | 343.2 | 468 |
Long Term Investments | 1834.2 | 801.6 | 585.5 | 506.3 | 567 |
Other Long Term Assets, Total | 357.5 | 350.5 | 274 | 207.6 | 276 |
Total Current Liabilities | 1032.3 | 893.9 | 902.4 | 876.6 | 1420 |
Accounts Payable | 204.5 | 196.5 | 180.4 | 134 | 116.6 |
Accrued Expenses | 714.2 | 578.7 | 642.7 | 510.2 | 516.1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 113.6 | 118.7 | 79.3 | 232.4 | 189.3 |
Total Liabilities | 2666.7 | 2662.8 | 2339.8 | 2183.3 | 2710.2 |
Total Long Term Debt | 595.7 | 595 | 594.4 | 593.8 | 438.4 |
Long Term Debt | 595.7 | 595 | 594.4 | 593.8 | 438.4 |
Other Liabilities, Total | 779.7 | 959.5 | 671.3 | 588 | 851.8 |
Total Equity | 5835.9 | 4574.3 | 4148.3 | 3140.4 | 2956.2 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 642 | 636.4 | 218.1 | 215.2 | 212 |
Additional Paid-In Capital | 1700.4 | 1438.1 | 1623.3 | 1384.4 | 1166.9 |
Retained Earnings (Accumulated Deficit) | 6068.1 | 4565 | 3741.6 | 2694.7 | 1962.1 |
Treasury Stock - Common | -2416.9 | -1904.1 | -1278.7 | -1015.4 | -252.1 |
Other Equity, Total | -150.8 | -169.7 | -157.7 | -133.5 | -128.1 |
Total Liabilities & Shareholders’ Equity | 8502.6 | 7237.1 | 6488.1 | 5323.7 | 5666.4 |
Total Common Shares Outstanding | 624.1 | 624.3 | 627.306 | 623.106 | 629.106 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 598 | |
Unrealized Gain (Loss) | -6.9 | 8.6 | 1.7 | -5 | -4.6 |
Property/Plant/Equipment, Total - Gross | 2293.3 | 2087.9 | 1652.7 | 1322.8 | |
Accumulated Depreciation, Total | -654.6 | -598.5 | -512.3 | -455.3 | |
Deferred Income Tax | 259 | 214.4 | 171.7 | 124.9 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Attivo Corrente | 3241.3 | 3180.7 | 3515.5 | 3322.9 | 3069.2 |
Disponibilità Liquide e Investimenti a Breve Termine | 1495.9 | 1466.8 | 1794.7 | 1561.2 | 1330.6 |
Disponibilità Liquide e Mezzi Equivalenti | 1030.9 | 862.8 | 1506.9 | 1312.8 | 1174.2 |
Investimenti a Breve Termine | 465 | 604 | 287.8 | 248.4 | 156.4 |
Totale Crediti, Netto | 686.2 | 664.9 | 664.2 | 700.3 | 664.3 |
Accounts Receivable - Trade, Net | 636.3 | 582.2 | 600.6 | 640.5 | 586.6 |
Total Inventory | 730.6 | 726.7 | 737.8 | 759.5 | 767.9 |
Prepaid Expenses | 94.1 | 85.2 | 76.9 | 68.6 | 77.3 |
Other Current Assets, Total | 234.5 | 237.1 | 241.9 | 233.3 | 229.1 |
Total Assets | 8419.9 | 8502.6 | 8160.3 | 7662.1 | 7213.7 |
Property/Plant/Equipment, Total - Net | 1642.3 | 1638.7 | 1549.4 | 1530.4 | 1506.4 |
Goodwill, Net | 1166.3 | 1167.9 | 1170.4 | 1171.8 | 1170.8 |
Intangibles, Net | 322 | 323.6 | 325.3 | 327 | 330.3 |
Long Term Investments | 1623.7 | 1834.2 | 1282 | 1014.2 | 802.2 |
Other Long Term Assets, Total | 424.3 | 357.5 | 317.7 | 295.8 | 334.8 |
Total Current Liabilities | 949.9 | 1032.3 | 966.5 | 886.2 | 799 |
Accounts Payable | 158.8 | 204.5 | 139.5 | 144.6 | 150.4 |
Accrued Expenses | 615.9 | 714.2 | 721.7 | 634.7 | 546.9 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 175.2 | 113.6 | 105.3 | 106.9 | 101.7 |
Total Liabilities | 2575 | 2666.7 | 2619 | 2528.8 | 2555.3 |
Total Long Term Debt | 595.9 | 595.7 | 595.5 | 595.4 | 595.2 |
Long Term Debt | 595.9 | 595.7 | 595.5 | 595.4 | 595.2 |
Deferred Income Tax | 270.7 | 259 | 245.4 | 234.2 | 224.2 |
Other Liabilities, Total | 758.5 | 779.7 | 811.6 | 813 | 936.9 |
Total Equity | 5844.9 | 5835.9 | 5541.3 | 5133.3 | 4658.4 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 642.9 | 642 | 641.2 | 640.1 | 637.5 |
Additional Paid-In Capital | 1769.4 | 1700.4 | 1643.1 | 1578.7 | 1496.8 |
Retained Earnings (Accumulated Deficit) | 6441.7 | 6068.1 | 5732.8 | 5392.7 | 4903.2 |
Treasury Stock - Common | -2822.5 | -2416.9 | -2320.4 | -2318.6 | -2206.7 |
Unrealized Gain (Loss) | -39.2 | -6.9 | 3 | 4.8 | 4.7 |
Other Equity, Total | -147.4 | -150.8 | -158.4 | -164.4 | -177.1 |
Total Liabilities & Shareholders’ Equity | 8419.9 | 8502.6 | 8160.3 | 7662.1 | 7213.7 |
Total Common Shares Outstanding | 621.4 | 624.1 | 624.2 | 623.1 | 621.8 |
- Annuale
- Trimestrale
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Reddito Netto/Linea di Partenza | 1503.1 | 823.4 | 1046.9 | 722.2 | 583.6 |
Liquidità da Attività Operative | 1732.1 | 1054.3 | 1179.4 | 926.8 | 1000.7 |
Liquidità da Attività Operative | 134.8 | 107.2 | 89.3 | 77.4 | 81.9 |
Deferred Taxes | -41.4 | -49.4 | 12.1 | -27.3 | 17.8 |
Elementi Non Monetari | -9.7 | 130.9 | 235.4 | 197.1 | 83.2 |
Cash Taxes Paid | 182.5 | 197.9 | 61.5 | 223.7 | 143.7 |
Interessi di Cassa Corrisposti | 20.2 | 19.9 | 19.9 | 30.1 | 19.9 |
Variazioni del Capitale Circolante | 145.3 | 42.2 | -204.3 | -42.6 | 234.2 |
Liquidità da Attività di Investimento | -1722.5 | -531.1 | -595.8 | 76.7 | -647.2 |
Spese in Conto Capitale | -329.8 | -407.3 | -278.4 | -241.7 | -175.5 |
Altri Elementi del Cash Flow da Investimenti, Totale | -1392.7 | -123.8 | -317.4 | 318.4 | -471.7 |
Liquidità da Attività di Finanziamento | -356.3 | -486.9 | -115.6 | -1101.2 | -473.2 |
Elementi del Cash Flow da Finanziamenti | -0.3 | -1.2 | -2.8 | -15.4 | 0 |
Emissione (Dismissione) di Azioni, Netto | -354.2 | -484.9 | -102.8 | -648.5 | -649.5 |
Emissione (Dismissione) di Debiti, Netto | -1.8 | -0.8 | -10 | -437.3 | 176.3 |
Effetti Cambi Valutari | 13.9 | -20.5 | -3 | -6.5 | 7.9 |
Variazione Netta della Liquidità | -332.8 | 15.8 | 465 | -104.2 | -111.8 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 373.6 | 1503.1 | 1167.8 | 827.7 | 338.2 |
Cash From Operating Activities | 293.3 | 1732.1 | 1358.5 | 826.6 | 300.5 |
Cash From Operating Activities | 34.7 | 134.8 | 101.8 | 68.2 | 32.4 |
Deferred Taxes | -42.6 | -41.4 | 20.1 | 16.2 | 10.8 |
Non-Cash Items | 57 | -9.7 | -15.8 | -47.5 | 28.3 |
Changes in Working Capital | -129.4 | 145.3 | 84.6 | -38 | -109.2 |
Cash From Investing Activities | 229.5 | -1722.5 | -756.6 | -379.2 | -49.7 |
Capital Expenditures | -72.7 | -329.8 | -236 | -175.3 | -106 |
Other Investing Cash Flow Items, Total | 302.2 | -1392.7 | -520.6 | -203.9 | 56.3 |
Cash From Financing Activities | -368.1 | -356.3 | -294.3 | -333.3 | -274.3 |
Financing Cash Flow Items | 0 | -0.3 | -1 | -3 | -2.9 |
Issuance (Retirement) of Stock, Net | -368.1 | -354.2 | -291.6 | -328.7 | -271 |
Issuance (Retirement) of Debt, Net | 0 | -1.8 | -1.7 | -1.6 | -0.4 |
Foreign Exchange Effects | 13.2 | 13.9 | 12.1 | 11.6 | 14.2 |
Net Change in Cash | 167.9 | -332.8 | 319.7 | 125.7 | -9.3 |
Nome investitore | Tipo investitore | Percentuale in circolazione | Azioni detenute | Variazione azioni | Data partecipazioni | Rating di turnover |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.4282 | 51269903 | 639997 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3695 | 32663343 | 1051645 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.488 | 27301166 | 493844 | 2022-12-31 | LOW |
Capital International Investors | Investment Advisor | 3.7385 | 22741986 | 44526 | 2022-12-31 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 3.6146 | 21988324 | 4770672 | 2022-12-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.5105 | 15271736 | 624619 | 2022-12-31 | LOW |
Brown Advisory | Investment Advisor/Hedge Fund | 2.3575 | 14341102 | 115268 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9951 | 12136243 | 205714 | 2022-12-31 | LOW |
Walter Scott & Partners Ltd. | Investment Advisor/Hedge Fund | 1.811 | 11016774 | -647534 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.4506 | 8824423 | 2342600 | 2022-12-31 | LOW |
Fisher Investments | Investment Advisor/Hedge Fund | 1.2613 | 7672618 | 133880 | 2022-12-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 1.2356 | 7516085 | -2889817 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 1.0808 | 6574509 | 4084454 | 2022-12-31 | HIGH |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.9468 | 5759351 | 129517 | 2022-12-31 | LOW |
Nuveen LLC | Pension Fund | 0.8833 | 5373020 | -65227 | 2022-12-31 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7864 | 4783540 | -652308 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 0.7454 | 4534155 | 2227180 | 2022-12-31 | HIGH |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7446 | 4529198 | -237259 | 2022-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7156 | 4353305 | 8792 | 2022-12-31 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 0.7115 | 4328367 | 473547 | 2022-12-31 | LOW |
Perché scegliere Capital.com? I nostri numeri parlano da soli.
Capital.com Group500K+
Traders
92K+
Clienti attivi mensilmente
$53M+
Volume di investimento mensile
$30M+
Prelevati mensilmente
Calcolatrice di trading
Calcola il tuo P&L ipotetico qualora avessi aperto un'operazione in CFD in una data specifica (seleziona una data) e l'avessi chiusa in una data diversa (seleziona una data).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Edwards Lifesciences Company profile
Su Edwards Lifesciences Corp
Edwards Lifesciences Corporation è un produttore di sistemi di valvole cardiache e prodotti di riparazione utilizzati per sostituire o riparare la valvola cardiaca malata o difettosa di un paziente. La Società è impegnata in innovazioni incentrate sul paziente per il monitoraggio delle malattie cardiache strutturali e delle cure critiche. I suoi segmenti includono Stati Uniti, Europa, Giappone e Resto del mondo. I suoi prodotti sono suddivisi in tre aree: Terapia della valvola cardiaca transcatetere, Terapia della valvola cardiaca chirurgica e Terapia critica. Sviluppa anche sistemi di monitoraggio emodinamico che vengono utilizzati per misurare la funzione cardiovascolare di un paziente in ambito ospedaliero. Sta sviluppando, tra gli altri, prodotti come il sistema Edwards SAPIEN 3 Ultra e la valvola cardiaca transcatetere Edwards SAPIEN XT. La sua terapia con valvola cardiaca transcatetere e la terapia con valvola cardiaca chirurgica sono prodotte negli Stati Uniti, a Singapore e in Svizzera. I prodotti di Terapia critica sono fabbricati nelle sue strutture situate a Puerto Rico e nella Repubblica Dominicana.
- IndustriaAdvanced Medical Equipment
- Indirizzo1 Edwards Way, IRVINE, CA, United States (USA)
- Dipendenti15700
- CEOMichael Mussallem
Industry: | Advanced Medical Equipment & Technology (NEC) |
One Edwards Way
92614
Conto Economico
- Annual
- Quarterly
Altri utenti guardano anche
Sei ancora alla ricerca di un broker di cui ti puoi fidare?
Unisciti agli oltre 500.000+ trader in tutto il mondo che hanno scelto di fare trading con Capital.com